Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMISIGHT Imaging in Excised Human Artery Plaques
NCT06957821Phase 1Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1 trial of pegulicianine in carotid artery disease and Peripheral Arterial Disease (PAD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Lumisight fluorescence activity. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
pegulicianine
03
Conditions
carotid artery diseasePeripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT06957821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957821.